



**FOR IMMEDIATE RELEASE**

CMD BIOSCIENCE APPOINTS BENJAMIN WOLOZIN, MD, PhD TO IT'S SCIENTIFIC ADVISORY BOARD

**ORANGE, Conn., March 31, 2010** -- CMD Bioscience, a CT based biotechnology company specializing in computer-aided peptide drug discovery, announced today the appointment of Benjamin Wolozin, M.D., Ph.D. to its scientific advisory board.

Benjamin Wolozin, M.D., Ph.D. is a professor of Pharmacology and Neurology at the Boston University School of Medicine. Dr. Wolozin's research investigates the pathophysiology of neurodegenerative diseases. His research on Parkinson's Disease focuses on understanding the interaction between genetic factors implicated in the disease and environmental factors utilizing cell culture, mammalian brain slice culture and transgenic lines of *C. elegans*. Results are then investigated further in transgenic/knockout mice and in human brain samples or cell lines from patients. His projects also focus on identifying pharmacological strategies for Parkinson's disease. The research on Alzheimer's disease focuses on the interaction between the proteins that produce beta-amyloid and the genes that regulate cholesterol metabolism. Finally, Dr. Wolozin has an active epidemiological research program that examines the effects of FDA-approved medications on the incidence and progression of both Alzheimer's and Parkinson's disease.

"It's an honor to announce the appointment of Dr Wolozin's to the CMD Bioscience Scientific Advisory Board. Dr Wolozin will provide outstanding clinical and drug discovery consultative services, especially concerning neurodegenerative diseases, an area of active research for CMD Bioscience. His leadership and experience offers excellent direction to our organization" said Dr. Joseph Audie, CEO and cofounder of CMD Bioscience.

CMD Bioscience, a privately held company based in Orange, CT, is an innovative leader in the development and application of advanced computational methodologies, expediting time to market for our partner's peptide-based products. Serving the pharmaceutical and biotech industries through international partnerships, collaborations, technologies and products, CMD Bioscience is setting the standard for computational peptide discovery.

To learn more about CMD Bioscience, please visit their website: <http://www.cmdbioscience.com>.

**CMD Bioscience media contact:**

Jennifer Muller  
Marketing On Demand  
860-604-6668  
[jmull@themodco.com](mailto:jmull@themodco.com)  
[www.cmdbioscience.com](http://www.cmdbioscience.com)